312 related articles for article (PubMed ID: 29048983)
1. Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015.
Chen A; Wright H; Itana H; Elahi M; Igun A; Soon G; Pariser AR; Fadiran EO
J Womens Health (Larchmt); 2018 Apr; 27(4):418-429. PubMed ID: 29048983
[TBL] [Abstract][Full Text] [Related]
2. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
Trials; 2016 Apr; 17():199. PubMed ID: 27079511
[TBL] [Abstract][Full Text] [Related]
3. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
[TBL] [Abstract][Full Text] [Related]
4. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.
Poon R; Khanijow K; Umarjee S; Fadiran E; Yu M; Zhang L; Parekh A
J Womens Health (Larchmt); 2013 Jul; 22(7):604-16. PubMed ID: 23768021
[TBL] [Abstract][Full Text] [Related]
5. Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs.
Khan MS; Shahid I; Siddiqi TJ; Khan SU; Warraich HJ; Greene SJ; Butler J; Michos ED
J Am Heart Assoc; 2020 Jun; 9(11):e015594. PubMed ID: 32427023
[TBL] [Abstract][Full Text] [Related]
6. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
[TBL] [Abstract][Full Text] [Related]
7. U.S. racial and ethnic participation in global clinical trials by therapeutic areas.
Lolic M; Araojo R; Okeke M; Temple R
J Clin Pharm Ther; 2021 Dec; 46(6):1576-1581. PubMed ID: 34544200
[TBL] [Abstract][Full Text] [Related]
8. Participation of racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular entities approved 1995-1999.
Evelyn B; Toigo T; Banks D; Pohl D; Gray K; Robins B; Ernat J
J Natl Med Assoc; 2001 Dec; 93(12 Suppl):18S-24S. PubMed ID: 11798060
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of worldwide clinical trials by gender: An FDA perspective.
Ayuso E; Geller RJ; Wang J; Whyte J; Jenkins M
Contemp Clin Trials; 2019 May; 80():16-21. PubMed ID: 30890465
[TBL] [Abstract][Full Text] [Related]
10. Demographic Disparities in the Federal Drug Approval Process for Allergic Rhinitis Medications.
Liebowitz A; Spielman DB; Schlosser RJ; Stewart MG; Gudis DA
Laryngoscope; 2023 Apr; 133(4):755-763. PubMed ID: 35394648
[TBL] [Abstract][Full Text] [Related]
11. Racial/Ethnic composition of study participants in FDA-approved oncology new molecular entities, 2006-2008.
Merenda C
J Natl Med Assoc; 2012; 104(9-10):430-5. PubMed ID: 23342816
[TBL] [Abstract][Full Text] [Related]
12. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
[TBL] [Abstract][Full Text] [Related]
13. Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs.
Scott PE; Unger EF; Jenkins MR; Southworth MR; McDowell TY; Geller RJ; Elahi M; Temple RJ; Woodcock J
J Am Coll Cardiol; 2018 May; 71(18):1960-1969. PubMed ID: 29724348
[TBL] [Abstract][Full Text] [Related]
14. Inclusion of Older People Reflective of Real-World Clinical Practice in Cardiovascular Drug Trials.
Caughey GE; Inacio MC; Bell JS; Vitry AI; Shakib S
J Am Heart Assoc; 2020 Nov; 9(21):e016936. PubMed ID: 33103558
[TBL] [Abstract][Full Text] [Related]
15. Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002.
Yang Y; Carlin AS; Faustino PJ; Motta MI; Hamad ML; He R; Watanuki Y; Pinnow EE; Khan MA
J Womens Health (Larchmt); 2009 Mar; 18(3):303-10. PubMed ID: 19243271
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
[TBL] [Abstract][Full Text] [Related]
17. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
18. Gender and Ethnicity of Enrolled Participants in U.S. Food and Drug Administration (FDA) Clinical Trials for Approved Ophthalmological New Molecular Entities.
Birnbaum FA
J Natl Med Assoc; 2018 Oct; 110(5):473-479. PubMed ID: 30129511
[TBL] [Abstract][Full Text] [Related]
19. New Benchmarks on Demographic Disparities in Pivotal Trials Supporting FDA-Approved Drugs and Biologics.
Smith Z; Botto E; Johnson O; Rudo T; Getz K
Ther Innov Regul Sci; 2024 Jan; 58(1):143-152. PubMed ID: 37775684
[TBL] [Abstract][Full Text] [Related]
20. Diversity in Orthopaedic Surgery Medical Device Clinical Trials: An Analysis of the Food and Drug Administration Safety and Innovation Act.
Issa TZ; Lambrechts MJ; Lin JS; Brush PL; Canseco JA; Hilibrand AS; Kepler CK; Schroeder GD; Vaccaro AR
J Am Acad Orthop Surg; 2023 Feb; 31(3):155-165. PubMed ID: 36525566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
